The coronavirus (COVID-19) pandemic is causing major disruptions to clinical trials, with one third of study sites anticipating closure and nearly 80% reporting at least
In 2018 Continuum Clinical conducted a social intelligence report—an analysis of online conversations centered around NASH. The report identified four key conversation themes: patient frustration,
Long before your study’s first randomization, before the first screening visit is scheduled, even before the very first patient is referred, sponsors have already invested
Goldman Sachs coined 2019 as the “Year of NASH.” They weren’t wrong, but it wasn’t all positive . . . this year, NASH is expected
An estimated 80% of clinical trials do not meet their patient enrollment goals1. Without enough patients to fill the trial, sponsors don’t have enough data
Without patients willing to enroll in clinical research, there would be no studies and therefore none of the potentially life-saving breakthroughs pharma is laboring to
There are countless challenges in implementing a global patient recruitment program—different cultures, multiple global gatekeepers, competing timelines and studies, multiple vendors, potentially varying protocols, and
Understanding Key Challenges The first step to successful NASH trial enrollment is acknowledging the many challenges we face. We know we need significant patient volume
Challenges in achieving total enrollment for your NASH clinical trial are everywhere—low awareness of the condition, extremely complex diagnosis pathways, high screen/failure rates, and a
When it comes to recruiting for a clinical trial, sponsors have one goal above all else: complete clinical trial enrollment. It is not enough for
2001 Pennsylvania Avenue, NW
Washington, D.C. 20006
